The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| RZLT | -37.87% | -82.09% | -29.09% | -100% |
| S&P | +14.77% | +87.2% | +13.35% | +358% |
Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperinsulinism, AB101-Phase 1, a once-weekly injectable basal insulin, and RZ402, which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.
No news articles found for Rezolute.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$8.00K | 0.0% |
| Market Cap | $853.63M | 217.9% |
| Market Cap / Employee | $12.02M | 0.0% |
| Employees | 71 | 20.3% |
| Net Income | -$18,150.00K | -18.0% |
| EBITDA | -$19,809.00K | -17.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $9.10M | -13.1% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $804.00K | -46.4% |
| Short Term Debt | $650.00K | 11.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -54.73% | 3.9% |
| Return On Invested Capital | -44.93% | 44.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$17,430.00K | 0.0% |
| Operating Free Cash Flow | -$17,430.00K | -8.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.39 | 1.76 | 3.27 | 5.04 | 136.34% |
| Price to Tangible Book Value | 2.39 | 1.76 | 3.27 | 5.04 | 136.34% |
| Enterprise Value to EBITDA | -14.53 | -5.89 | -9.85 | -41.47 | 202.62% |
| Return on Equity | -74.4% | -95.2% | -52.6% | -59.2% | -7.28% |
| Total Debt | $1.93M | $1.78M | $1.62M | $1.45M | -30.20% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
